Background-Data are limited regarding whether the presence of diabetes mellitus (DM) influences the benefit of cardiac resynchronization with defibrillator therapy (CRT-D) in heart failure (HF) patients. Methods and Results-The effect of CRT-D was evaluated in 1817 patients who were enrolled in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). Patients were minimally symptomatic (New York Heart Association class I or II), with ejection fraction Յ0.30 and QRS Ն130 ms. We used Cox regression to determine hazard ratio (HR) of CRT-D versus implantable cardioverter-defibrillator (ICD) therapy for the risk of HF event or death, whichever came first (MADIT-CRT primary end point), in DM (nϭ552) and non-DM (nϭ1265) patients. Compared with the non-DM patients, those with DM had more coronary risk factors. During an average follow-up of 2.4 years, DM patients had significantly more primary end point events than non-DM patients (26.6% versus 18%, PϽ0.001). CRT-D was associated with a significant reduction in risk of primary end point in both DM (HRϭ0.56, PϽ0.001) and non-DM patients (HRϭ0.67, Pϭ0.003). Compared with non-DM patients, CRT-D:ICD HRs in DM patients were lower in the total population, and in subgroups with ischemic cardiomyopathy (0.63 versus 0.64), nonischemic cardiomyopathy (0.39 versus 0.73), and left bundle-branch block (0.36 versus 0.50). There were no significant differences in ventricular remodeling, arrhythmia events, or device-related complications between DM and non-DM patients. Conclusions-Patients with diabetes, left ventricular dysfunction, mildly symptomatic HF, and wide QRS complex derive similar benefit from CRT-D compared with patients without diabetes. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00180271. (Circ Heart Fail. 2011;4:332-338.)
T he use of implantable cardioverter-defibrillators (ICD) in patients at risk for sudden cardiac death is now well established. [1] [2] [3] In appropriately selected patients with left ventricular dysfunction, heart failure symptoms, and ECG evidence of intraventricular conduction delay, implantation of an automatic defibrillator with additional cardiac resynchronization (biventricular pacing, CRT-D) function has been shown to reduce the frequency of heart failure events and to improve objective measurements of cardiac function. 4 -6 
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Patients with diabetes are at increased risk for both sudden cardiac death and heart failure. [7] [8] [9] However, little is known of the outcome of patients with diabetes who receive device therapy for reducing the risk of heart failure. We therefore performed a substudy analysis of the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) trial to assess the effectiveness of CRT-D therapy in patients with and without diabetes.
Methods
The primary results of the MADIT-CRT trial have been previously reported. 4 Briefly, this was a randomized, controlled clinical of 1820 patients enrolled at 110 hospitals in the United States, Canada, and Europe between December 2004 and April 2008. Minimally symptomatic (New York Heart Association [NYHA] class I or II) patients with left ventricular dysfunction (ejection fraction of Յ30%) and prolonged intraventricular conduction (QRS duration, Ն130 ms) were randomly assigned in a 3:2 ratio to receive cardiac resynchro-nization with defibrillator (CRT-D) or an ICD only. The primary end point was death from any cause or nonfatal heart failure events, whichever came first.
We undertook a substudy analysis of this large trial and compared the effects of resynchronization therapy on cardiac events in those patients with and without diabetes. Patients with diabetes were defined in the original MADIT-CRT protocol as those receiving either oral hypoglycemic agents or insulin at the time of enrollment. Ischemic heart disease was defined by a history of myocardial infarction or coronary revascularization procedure Ͼ90 days before enrolment (NYHA class I or II); patients with nonischemic cardiomyopathy were eligible for enrollment if they met the eligibility criteria for ejection fraction and QRS duration in the absence of any evidence of coronary disease and were in NYHA class II for Ͼ90 days. Left bundle-branch block was defined using the World Health Organization Task Force criteria. 10
Statistical Analysis
We performed Kaplan-Meier survival analyses of unadjusted cumulative event rates stratified by diabetes status for patients randomly assigned to ICD and CRT-D. The log-rank statistic was used for determination of statistical significance. We estimated CRT-D to ICD hazard ratios for risk of heart failure or death, whichever came first, for all patients, for patients with ischemic and nonischemic cardiomyopathy, and for patients with left bundle-branch block, using the Cox proportional hazards regression method. 11 The regression model was adjusted for factors that could play a role in heart failure or coronary artery disease (age, hypertension, prior myocardial infarction, prior revascularization surgery, body mass index, serum creatinine, diuretic use, statin use, and calcium channel blocker use). Adjusted model-based cumulative event rates were based on the baseline survival function from this multivariate Cox model. The mean values of the covariates in the 4 treatment/diabetes subgroups were used to specify the baseline survival functions from which the 2-year event rates were estimated. To assess the CRT-D treatment differences between patients with and without diabetes, a treatment-by-diabetes status interaction term was included in the Cox proportional hazard regression models. All probability values were 2-tailed, and PϽ0.05 was considered significant.
Results
There were 552 patients with diabetes enrolled in MADIT-CRT (30% of the total study population); their clinical characteristics compared with those without diabetes are provided in Table 1 . There were 3 patients for whom diabetic status at enrollment could not be definitively ascertained. Patients with diabetes were equally distributed between the ICD and CRT-D arms of the trial; patients with diabetes tended to be older and were more likely to have a history of ischemic heart disease (with both myocardial infarction and previous coronary artery bypass surgery being more frequent), hypertension, and renal dysfunction than patients without diabetes. Patients with diabetes were more likely to be nonwhite and African-American. Although there was no difference in mean ejection fraction at enrollment, patients with diabetes were more likely to be obese and have higher brain natriuretic peptide levels. Despite slightly lower left ventricular volume measurements, patients with diabetes had less exercise capacity and were more likely to be receiving diuretic therapy than patients without diabetes.
The primary end point of death or heart failure event, whichever occurred first, occurred in 26.6% of the patients with diabetes and in 18% of those without diabetes (PϽ0.001), with death and heart failure events being more frequent in the diabetes group. This higher event rate in the patients with diabetes was seen in both treatment arms: 35% versus 21.9% in the ICD arm (PϽ0.001) and 21.3% versus 15.4% in the CRT-D arm (Pϭ0.019). Kaplan-Meier estimates of the cumulative probability of an end point event in patients with and without diabetes are presented in the Figure. The outcome events were significantly less frequent in CRT-D-treated patients than in the ICD-treated patients in both the diabetes and no-diabetes groups, and there was a suggestion of earlier and greater benefit from CRT-D therapy in patients with diabetes ( Figure, A and B) .
The rates of operative complications with device implantation including infection were similar in those with and without diabetes, and there were no differences between these groups regarding the frequency of appropriate and inappropriate defibrillator therapies ( Table 2) .
Both unadjusted and adjusted hazard ratios for the risk of heart failure or death, whichever occurred first, among patients with and without diabetes randomly assigned to CRT-D versus ICD, are presented in Table 3 . Both groups derived significant reduction in risk of cardiac events from CRT-D therapy, but the patients with diabetes exhibited a 44% reduction compared with a 33% reduction in patients without diabetes (the probability value for the diabetesϫ treatment interaction was not significant). The patients with diabetes who had nonischemic heart disease and those with left bundle-branch block had numerically greater reductions in risk of cardiac events with CRT-D therapy than did the patients without diabetes. However, there were no significant diabetesϫtreatment interactions in these subgroups. The unadjusted Kaplan-Meier estimate of the number needed to treat (NNT) over 2 years to prevent 1 death or heart failure event (whichever occurred first) was 6.9 (95% confidence interval [CI], 4.5 to 15.0) for patients with diabetes compared with 17.5 (95% CI, 10.0 to 73.5) for patients without diabetes (Pϭ0.054). The NNT based on the unadjusted Cox model was 9.7 (95% CI, 6.2 to 23.2) for patients with diabetes and 14.3 (95% CI, 9.4 to 29.3) for patients without diabetes (Pϭ0.358); after adjustment, the NNT over 2 years to prevent 1 death or heart failure event was 10.0 (95% CI, 6.2 to 25.1) and 16.6 (95% CI, 10.5 to 39.7), respectively (Pϭ0.261).
Between baseline and 1 year, diabetic and nondiabetic groups exhibited similar improvement with CRT-D therapy in echocardiographic indices: Left ventricular end-diastolic volume index declined in ICD-treated patients (diabetes: 6.5Ϯ6.3 mL/m 2 versus no diabetes: 7.7Ϯ7.4 mL/m 2 , PϭNS) and in CRT-D-treated patients (diabetes: 25.6Ϯ14.5 mL/m 2 versus no diabetes: 26.3Ϯ17.3 mL/m 2 , PϭNS). Left ventricular ejection fraction increased in ICD-treated patients (diabetes: 3.3Ϯ2.9% versus no diabetes: 3.4Ϯ3.1%, PϭNS) and in CRT-D-treated patients (diabetes: 10.9Ϯ4.8% versus no diabetes: 11.1Ϯ5.4%, PϭNS).
Discussion
The data from this substudy of MADIT-CRT show that mildly symptomatic patients with diabetes and left ventricular systolic dysfunction have a greater risk of heart failure events and mortality than patients without diabetes. In patients with diabetes, the benefits derived from cardiac resynchronization therapy were at least as impressive as those observed in patients without diabetes. Resynchronization therapy exerts similar effects on ventricular remodeling in both groups, as shown in the echocardiographic findings. This is the largest study describing outcomes in patients with diabetes treated with CRT and is the only such study that has examined functional patients enrolled at a relatively early stage in the evolution of the heart failure syndrome.
Patients with diabetes are at increased risk of development of heart failure, independent of the presence of coronary artery disease. Among patients with heart failure, the presence of diabetes is associated with a worse overall prognosis. [12] [13] [14] Our data suggest that patients with diabetes receiving evidence-based pharmacological treatment for heart failure continue to exhibit a worse overall prognosis regarding both death and heart failure events compared with patients without diabetes, and this is consistent with other recently published reports. 15 Interestingly, the adverse outcomes experienced by patients with diabetes appear unrelated to ventricular arrhythmia or to device-related complications, both of which were similar in frequency in the diabetes and no-diabetes groups.
Although many previous studies have reported on the excess mortality and morbidity of patients with diabetes as well as on the similar responses of patients with and without diabetes to medical therapy of heart failure, 16 data are limited comparing patients with and without diabetes who receive CRT or ICD therapy. Small observational studies have suggested that patients with diabetes who also have severe heart failure derive similar benefits from CRT when compared with patients without diabetes. 17, 18 However, other observational reports suggest that patients with both diabetes and ischemic heart disease as well as those treated with insulin obtain little or no benefit from CRT. 19, 20 Data derived from randomized, clinical trials of CRT in advanced (NYHA class III and IV) heart failure have recently been analyzed in relation to the impact of diabetes on therapeutic responses, and these reports are consistent with our findings. 21, 22 The Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial enrolled 1520 patients with NYHA class III or IV heart failure, ejection fraction Յ0.35, QRS interval Ն120 ms, sinus rhythm, and PR interval Ն150 ms who had been hospitalized for heart failure in the preceding 12 months. 6 This was the first trial to show that CRT-D was associated with mortality reduction in addition to improvement in functional capacity and quality of life. A diabetes substudy of COMPANION reported that when CRT-D-treated and CRT-pacemakertreated patients with diabetes were combined and compared with medically treated patients with diabetes, CRT therapy was associated with a one-third reduction in the risk of mortality and a 50% reduction in pump failure death 21 ; this reduction in risk in patients with advanced heart failure is broadly similar to the reduction in event rates shown in our study of patients with diabetes and mild heart failure.
A post hoc subgroup analysis of the 207 patients with diabetes in the Cardiac Resynchronization in Heart Failure (CARE-HF) trial was performed to determine the effect of CRT on the risk of complications and death when compared with standard pharmacological therapy in patients with heart failure. Patients in this study had left ventricular systolic dysfunction, markers of cardiac dyssynchrony, and symptomatic heart failure. In keeping with the results of our study and the COMPANION trial, the CARE-HF analysis showed that CRT reduced all-cause mortality, heart failure hospitalization, and vascular events as well as causing similar improvements in left ventricular ejection fraction and end-systolic volume index in patients with and without diabetes. In addition, there was no significant difference in clinical benefit when patients with and without diabetes were compared. Although patients enrolled in CARE-HF exhibited advanced heart failure, these findings are comparable to our data derived from patients with class I and II symptoms.
The prevalence of known diabetes in our study (30%) was high and was similar to that observed in the CARE-HF trial (29%) but was less than in the COMPANION trial (41%). These differences may be explained in part by different methods of ascertainment of diabetes status because other clinical characteristics in all these studies appear to be generally similar. The close links between prevalent diabetes and heart failure 23 and the possible bidirectional causal relationship 24 are well recognized.
Our analysis suggests that in defibrillator-treated patients with diabetes, CRT therapy is particularly beneficial in subgroups with ischemic heart disease, nonischemic cardiomyopathy and in those with left bundle-branch block. The reduction in the risk of death or hospitalization is especially striking for the latter 2 groups, in whom the risk of events was reduced by Ͼ50%, and is much greater than the effect of standard heart failure drug treatments in diabetes. 16 There have been no previous studies that have examined clinical responses to CRT therapy in these subgroups with diabetes. We believe that our data should be considered hypothesisgenerating and that future studies should be designed to explore potential mechanisms of benefit, which might include beneficial changes in diastolic function and left ventricular mass.
We have also shown that the presence of diabetes does not influence the effect of CRT therapy on left ventricular end-diastolic volume and left ventricular ejection fraction. These findings are in keeping with those from the CARE-HF diabetes substudy 22 but are in contrast to those from a smaller study of 130 CRT-treated patients, in which the presence of diabetes (nϭ30) was associated with less improvement in left ventricular end-systolic volume, mitral annular tissue velocity, and left ventricular filling pressures after CRT. 19 There are several potential mechanisms that could, at least in theory, lead to differences in the response to CRT therapy in patients with and those without diabetes. Myocardial fat content, 25 fibrosis and collagen deposition, 26 cardiac autonomic function, 27 and myocardial blood flow 28 have been found to be altered in the presence of diabetes and therefore these might influence the clinical impact of CRT. However, our study has suggested that patients with diabetes benefit from CRT therapy similarly to patients without diabetes. Larger studies are required to confirm this and to elucidate whether any of the pathophysiological differences determine the response to CRT between patients with and without diabetes.
Our study is limited by potential classification bias because the definition of diabetes in MADIT-CRT was confined to those patients receiving oral or insulin therapy; therefore patients with diet-controlled diabetes remain unidentified in this substudy and were classified with the no-diabetes group. However, such misclassification would be expected to reduce the differences between patients with and without diabetes. Similarly, our study does not permit assessment of outcomes and responses to therapy in relation to glycemic control because glycosylated hemoglobin was not measured in MADIT-CRT. The lack of a significant diabetesϫtreatment interaction may reflect reduced power from the limited sample size.
In conclusion, our data suggest that despite worse overall outcomes, patients with diabetes obtain a similar degree of benefit from CRT-D when compared with patients without diabetes. Further study will be required to prospectively identify the mechanisms underlying the different outcomes in patients with and without diabetes with minimally symptomatic heart failure. 
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